{"protocolSection":{"identificationModule":{"nctId":"NCT00707967","orgStudyIdInfo":{"id":"111517"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.","officialTitle":"Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) in HIV-positive Adults."},"statusModule":{"statusVerifiedDate":"2016-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-06-30"},"primaryCompletionDateStruct":{"date":"2009-05-27","type":"ACTUAL"},"completionDateStruct":{"date":"2009-05-27","type":"ACTUAL"},"studyFirstSubmitDate":"2008-06-27","studyFirstSubmitQcDate":"2008-06-27","studyFirstPostDateStruct":{"date":"2008-07-01","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-11-07","resultsFirstSubmitQcDate":"2016-11-07","resultsFirstPostDateStruct":{"date":"2017-01-06","type":"ESTIMATED"},"dispFirstSubmitDate":"2009-09-03","dispFirstSubmitQcDate":"2009-09-03","dispFirstPostDateStruct":{"date":"2009-09-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-07-26","lastUpdatePostDateStruct":{"date":"2018-08-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine (692342) administered at 0, 1 month to HIV-positive adults living in Switzerland."},"conditionsModule":{"conditions":["Tuberculosis"],"keywords":["Tuberculosis vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":37,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","description":"Subjects receiving the candidate vaccine","interventionNames":["Biological: GSK's candidate Mycobacterium tuberculosis vaccine 692342"]},{"label":"Group B","type":"PLACEBO_COMPARATOR","description":"Subjects receiving the adjuvant","interventionNames":["Biological: Control vaccine with the adjuvant system."]},{"label":"Group C","type":"PLACEBO_COMPARATOR","description":"Subjects receiving physiological saline","interventionNames":["Biological: Control vaccine with physiological saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"GSK's candidate Mycobacterium tuberculosis vaccine 692342","description":"Intramuscular injection, 2 doses at 0, 1 month","armGroupLabels":["Group A"]},{"type":"BIOLOGICAL","name":"Control vaccine with the adjuvant system.","description":"Intramuscular injection, 2 doses at 0, 1 month","armGroupLabels":["Group B"]},{"type":"BIOLOGICAL","name":"Control vaccine with physiological saline","description":"Intramuscular injection, 2 doses at 0, 1 month","armGroupLabels":["Group C"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed.","timeFrame":"During the 7-day period (Days 0-6) post vaccination following each dose"},{"measure":"Number of Subjects With Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, temperature \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\], gastrointestinal symptoms (gastro) \\[nausea, vomiting, diarrhoea and/or abdominal pain\\], headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.","timeFrame":"During the 7-day period (Days 0-6) post vaccination following each dose"},{"measure":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","timeFrame":"During the 30-day period (Days 0-29) post vaccination"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity","timeFrame":"During the entire study period, from Day 0 up to Day 210"},{"measure":"Number of Subjects With Normal Biochemical and Haematological Levels","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Normal Haematological Levels","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Normal Haematological Levels","description":"Among biochemical and haematological parameters assessed were platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Biochemical and Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Biochemical and Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"},{"measure":"Number of Subjects With Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","timeFrame":"At Day 0, 7, 30, 37 and 60"}],"secondaryOutcomes":[{"measure":"Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines","description":"Among cytokines expressed were interleukin-2 \\[IL-2\\] and/or interferon-gamma \\[IFN-γ\\] and/or tumour necrosis factor-alpha \\[TNF-α\\] and/or cluster of differentiation 40-ligand \\[CD40-L\\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).","timeFrame":"At Day 0, 30, 60 and 210"},{"measure":"Frequency of M72 Specific CD4/8+ T Cells Expressing at Least One Cytokine and Another Signal Molecule","description":"Expressed cytokine combinations for CD4+ T cells were CD40-L and interleukin-2 \\[IL-2\\] or interferon-gamma \\[IFN-γ\\] or tumour necrosis factor-alpha \\[TNF-α\\]; IL-2 and CD40-L, or IFN-γ, or TNF-α; IFN-γ and CD40-L, or IL-2, or TNF-α; TNF-α and CD40-L, or IL-2, or IFN-γ.\n\nFor CD8+ T cells no vaccine induced responses were observed, thus results are presented only for the frequency of M72-specific CD8+ T cells expressing at least two cytokines.","timeFrame":"At Day 0, 30, 60 and 210"},{"measure":"Cell Count of CD4+ T Cells","description":"CD4+ T cell counts are defined by values greater than (\\>) 200 cells per cubic millimeters (mm3) at screening for enrolment into the study.","timeFrame":"At Day 0, 30, 60 and 210"},{"measure":"Anti-M72 Specific Antibody Concentrations","description":"Concentrations given in Enzyme-Linked Immunosorbent Assay units per milliliter (EL.U/mL) were expressed in Geometric Mean Concentrations (GMCs).","timeFrame":"At Day 0, 30, 60 and 210"},{"measure":"Number of Subjects With Significant Highly Active Anti-Retroviral Therapy (HAART) Changes","description":"Recorded significant HAART change refers to one subject switching the Combivir drug to Truvada as planned by personal physician, with no relationship to vaccination, prior to study enrolment.","timeFrame":"From Day 60 to Day 210"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol.\n* A male or female between, and including, 18 and 50 years of age at the time of the first vaccination.\n* Written informed consent obtained from the subject prior to any study procedure.\n* Subjects must be HIV-positive and must have:\n\n  * received Highly Active Antiretroviral therapy for a minimum of 12 consecutive months prior to screening\n  * documented suppressed HIV-1 RNA levels following HAART-treatment.\n  * a protocol defined CD4+ T cell count at screening\n* If the subject is female, she must be of non-childbearing potential, or she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of vaccination.\n* Clinically acceptable laboratory values prior to randomisation as determined by the Investigator.\n* No evidence of TB disease with no pulmonary pathology as confirmed by chest X-ray.\n* No history of extrapulmonary TB.\n* No history of chemotherapy for TB.\n\nExclusion Criteria:\n\n* Any change in antiretroviral drug regimen within 12 weeks prior to screening.\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Administration of a registered live vaccine not foreseen by the study within 30 days preceding the first dose of study vaccine and administration of a registered inactivated vaccine within 14 days preceding the first dose of study vaccine.\n* History of previous administration of experimental Mycobacterium tuberculosis vaccines.\n* History of previous exposure to experimental products containing components of the experimental vaccine.\n* Chronic administration of immunosuppressive or other immune-modifying drugs within six months prior to the first vaccine dose.\n* Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.\n* Any condition or illness (acute, chronic or history) or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine.\n* Planned participation or participation in another experimental protocol during the study period.\n* A family history of congenital or hereditary immunodeficiency. •Any chronic drug therapy, other than HAART or prophylaxis for opportunistic HIV-related infections to be continued during the study period. Vitamins and/or dietary supplements, birth control pills, anti-histamines for seasonal allergies and SSRIs are allowed.\n* Subjects taking any of the following medication: systemic steroids, interleukins, systemic interferons or systemic chemotherapy.\n* History of allergic reactions or anaphylaxis to any vaccine.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\n* History of chronic alcohol consumption and/or drug abuse which in the Investigator's opinion would put the subject at risk.\n* Pregnant female, lactating female or female planning to become pregnant or stop contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}}]},"referencesModule":{"references":[{"pmid":"24911353","type":"DERIVED","citation":"Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitie MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS. 2014 Jul 31;28(12):1769-81. doi: 10.1097/QAD.0000000000000343."},{"pmid":"24864125","type":"DERIVED","citation":"Roy-Ghanta S, Van der Most R, Li P, Vaughn DW. Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. J Infect Dis. 2014 Nov 1;210(9):1419-30. doi: 10.1093/infdis/jiu284. Epub 2014 May 26."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.","groups":[{"id":"FG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"FG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"FG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"BG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"BG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"37"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39.6","spread":"7.43"},{"groupId":"BG001","value":"40.0","spread":"5.61"},{"groupId":"BG002","value":"41.9","spread":"4.67"},{"groupId":"BG003","value":"40.12","spread":"6.54"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"11"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"26"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the 7-day period (Days 0-6) post vaccination following each dose","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Any Pain, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Pain, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Redness, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Redness, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Swelling, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Pain, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Pain, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Redness, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Redness, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Swelling, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Pain, Across","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Pain, Across","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Redness, Across","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Redness, Across","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Swelling, Across","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Swelling, Across","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, temperature \\[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\\], gastrointestinal symptoms (gastro) \\[nausea, vomiting, diarrhoea and/or abdominal pain\\], headache, malaise and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever ≥ 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the 7-day period (Days 0-6) post vaccination following each dose","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Any Fatigue, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Fatigue, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Fatigue, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Gastro, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Gastro, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Gastro, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Headache, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Headache, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Headache, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Malaise, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Malaise, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Malaise, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Myalgia, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Myalgia, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Myalgia, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Temperature, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Temperature, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Temperature, Dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Fatigue, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Fatigue, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Fatigue, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Gastro, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Gastro, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Gastro, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Headache, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"Grade 3 Headache, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Headache, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Malaise, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Malaise, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Malaise, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Myalgia, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Myalgia, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Related Myalgia, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Temperature, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Grade 3 Temperature, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Temperature, Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Fatigue, Across","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Fatigue, Across","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Fatigue, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Gastro, Across","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Gastro, Across","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Gastro, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Headache, Across","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}]}]},{"title":"Grade 3 Headache, Across","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Headache, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Malaise, Across","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Malaise, Across","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Malaise, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Myalgia, Across","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Myalgia, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"Related Myalgia, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Any Temperature, Across","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Grade 3 Temperature, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related Temperature, Across","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the 30-day period (Days 0-29) post vaccination","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Any AEs","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}]}]},{"title":"Grade 3 AEs","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Related AEs","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"During the entire study period, from Day 0 up to Day 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Normal Biochemical and Haematological Levels","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"ALT, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"}]}]},{"title":"ALT, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"}]}]},{"title":"ALT, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"}]}]},{"title":"ALT, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"ALT, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"AST, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"AST, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"}]}]},{"title":"AST, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}]}]},{"title":"AST, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"}]}]},{"title":"AST, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"BAS, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}]}]},{"title":"BAS, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}]},{"title":"BAS, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}]}]},{"title":"BAS, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"BAS, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"CREA, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"CREA, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"CREA, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"CREA, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"CREA, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"EOS, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"EOS, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"EOS, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}]},{"title":"EOS, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"EOS, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Normal Haematological Levels","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Hct, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hct, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hct, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hct, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hct, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hgb, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hgb, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hgb, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hgb, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"Hgb, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"LYM, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"LYM, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"LYM, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"LYM, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"LYM, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}]}]},{"title":"MON, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}]},{"title":"MON, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}]},{"title":"MON, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}]},{"title":"MON, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}]},{"title":"MON, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"NEU, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"NEU, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"NEU, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]},{"title":"NEU, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"NEU, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Normal Haematological Levels","description":"Among biochemical and haematological parameters assessed were platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"PLA, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"PLA, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"}]}]},{"title":"PLA, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"}]}]},{"title":"PLA, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"PLA, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}]},{"title":"RBC, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}]}]},{"title":"RBC, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}]}]},{"title":"RBC, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"RBC, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}]}]},{"title":"RBC, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}]},{"title":"WBC, Day 0-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"WBC, Day 7-normal","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}]},{"title":"WBC, Day 30-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}]}]},{"title":"WBC, Day 37-normal","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}]}]},{"title":"WBC, Day 60-normal","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Biochemical and Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"ALT, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"BAS, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"BAS, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"BAS, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"BAS, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"BAS, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"CREA, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"CREA, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"CREA, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"EOS, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"EOS, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"EOS, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"EOS, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"EOS, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Hct, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Haematological Levels Below Normal","description":"Among biochemical and haematological parameters assessed were \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"PLA, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"PLA, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"RBC, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"RBC, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"RBC, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"RBC, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"RBC, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"WBC, Day 0-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"WBC, Day 7-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"WBC, Day 30-below","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"WBC, Day 37-below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"WBC, Day 60-below","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Biochemical and Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CREA\\], eosinophil \\[EOS\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"ALT, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}]},{"title":"ALT, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"ALT, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]},{"title":"AST, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]},{"title":"AST, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}]},{"title":"AST, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}]}]},{"title":"AST, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"BAS, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"BAS, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"BAS, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"BAS, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"BAS, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"CREA, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"CREA, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"EOS, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"EOS, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"EOS, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"EOS, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"EOS, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were haematocrit \\[Hct\\], haemoglobin \\[Hgb\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Hct, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hct, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Hgb, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"LYM, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"LYM, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"LYM, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"MON, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"MON, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"MON, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"MON, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"NEU, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"NEU, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"NEU, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"NEU, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Haematological Levels Above Normal","description":"Among biochemical and haematological parameters assessed were \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - normal, below and above.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"At Day 0, 7, 30, 37 and 60","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"PLA, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"PLA, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"RBC, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"RBC, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"RBC, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"RBC, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"RBC, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"WBC, Day 0-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"WBC, Day 7-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]},{"title":"WBC, Day 30-above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]},{"title":"WBC, Day 37-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}]}]},{"title":"WBC, Day 60-above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]}]},{"type":"SECONDARY","title":"Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation 4/8 (CD4/8+) T Cells Expressing at Least Two Different Cytokines","description":"Among cytokines expressed were interleukin-2 \\[IL-2\\] and/or interferon-gamma \\[IFN-γ\\] and/or tumour necrosis factor-alpha \\[TNF-α\\] and/or cluster of differentiation 40-ligand \\[CD40-L\\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).","populationDescription":"The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome variables were available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"T cells/million cells","timeFrame":"At Day 0, 30, 60 and 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"CD4-All Doubles, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"95.0","lowerLimit":"1.0","upperLimit":"218.0"},{"groupId":"OG001","value":"154.5","lowerLimit":"40.5","upperLimit":"160.5"},{"groupId":"OG002","value":"96.0","lowerLimit":"1.0","upperLimit":"267.0"}]}]},{"title":"CD4-All Doubles, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"1713.5","lowerLimit":"507.0","upperLimit":"2786.0"},{"groupId":"OG001","value":"129.0","lowerLimit":"103.5","upperLimit":"204.5"},{"groupId":"OG002","value":"94.0","lowerLimit":"1.0","upperLimit":"226.0"}]}]},{"title":"CD4-All Doubles, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"7003.5","lowerLimit":"3691.0","upperLimit":"10701.0"},{"groupId":"OG001","value":"112.0","lowerLimit":"51.0","upperLimit":"258.0"},{"groupId":"OG002","value":"26.0","lowerLimit":"13.0","upperLimit":"227.0"}]}]},{"title":"CD4-All Doubles, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"4245.0","lowerLimit":"2427.0","upperLimit":"6121.0"},{"groupId":"OG001","value":"83.5","lowerLimit":"16.0","upperLimit":"140.0"},{"groupId":"OG002","value":"67.0","lowerLimit":"4.0","upperLimit":"133.0"}]}]},{"title":"CD8-All Doubles, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"167.0","lowerLimit":"1.0","upperLimit":"358.0"},{"groupId":"OG001","value":"71.5","lowerLimit":"11.0","upperLimit":"442.0"},{"groupId":"OG002","value":"364.0","lowerLimit":"80.0","upperLimit":"1001.0"}]}]},{"title":"CD8-All Doubles, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"97.0","lowerLimit":"27.0","upperLimit":"507.0"},{"groupId":"OG001","value":"38.5","lowerLimit":"8.0","upperLimit":"293.0"},{"groupId":"OG002","value":"216.0","lowerLimit":"1.0","upperLimit":"986.0"}]}]},{"title":"CD8-All Doubles, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"236.0","lowerLimit":"19.0","upperLimit":"542.0"},{"groupId":"OG001","value":"74.5","lowerLimit":"1.0","upperLimit":"570.0"},{"groupId":"OG002","value":"415.0","lowerLimit":"25.0","upperLimit":"889.0"}]}]},{"title":"CD8-All Doubles, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"195.0","lowerLimit":"20.0","upperLimit":"340.0"},{"groupId":"OG001","value":"55.5","lowerLimit":"1.0","upperLimit":"248.5"},{"groupId":"OG002","value":"241.0","lowerLimit":"39.0","upperLimit":"858.0"}]}]}]},{"type":"SECONDARY","title":"Frequency of M72 Specific CD4/8+ T Cells Expressing at Least One Cytokine and Another Signal Molecule","description":"Expressed cytokine combinations for CD4+ T cells were CD40-L and interleukin-2 \\[IL-2\\] or interferon-gamma \\[IFN-γ\\] or tumour necrosis factor-alpha \\[TNF-α\\]; IL-2 and CD40-L, or IFN-γ, or TNF-α; IFN-γ and CD40-L, or IL-2, or TNF-α; TNF-α and CD40-L, or IL-2, or IFN-γ.\n\nFor CD8+ T cells no vaccine induced responses were observed, thus results are presented only for the frequency of M72-specific CD8+ T cells expressing at least two cytokines.","populationDescription":"The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome variables were available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"T cells/million cells","timeFrame":"At Day 0, 30, 60 and 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"CD4-CD40-L, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"88.5","lowerLimit":"26.0","upperLimit":"185.0"},{"groupId":"OG001","value":"135.0","lowerLimit":"54.0","upperLimit":"152.0"},{"groupId":"OG002","value":"110.0","lowerLimit":"1.0","upperLimit":"240.0"}]}]},{"title":"CD4-CD40-L, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"1389.5","lowerLimit":"506.0","upperLimit":"2359.0"},{"groupId":"OG001","value":"129.0","lowerLimit":"71.5","upperLimit":"196.5"},{"groupId":"OG002","value":"94.0","lowerLimit":"1.0","upperLimit":"226.0"}]}]},{"title":"CD4-CD40-L, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"6771.5","lowerLimit":"3334.0","upperLimit":"10235.0"},{"groupId":"OG001","value":"112.0","lowerLimit":"54.5","upperLimit":"211.5"},{"groupId":"OG002","value":"40.0","lowerLimit":"26.0","upperLimit":"213.0"}]}]},{"title":"CD4-CD40-L, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"3953.0","lowerLimit":"1477.0","upperLimit":"4853.0"},{"groupId":"OG001","value":"71.0","lowerLimit":"1.0","upperLimit":"145.0"},{"groupId":"OG002","value":"53.0","lowerLimit":"1.0","upperLimit":"120.0"}]}]},{"title":"CD4-IL-2, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"104.0","lowerLimit":"40.0","upperLimit":"160.0"},{"groupId":"OG001","value":"87.0","lowerLimit":"52.5","upperLimit":"118.0"},{"groupId":"OG002","value":"120.0","lowerLimit":"13.0","upperLimit":"267.0"}]}]},{"title":"CD4-IL-2, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"1140.0","lowerLimit":"427.0","upperLimit":"2141.0"},{"groupId":"OG001","value":"136.5","lowerLimit":"58.0","upperLimit":"200.0"},{"groupId":"OG002","value":"93.0","lowerLimit":"12.0","upperLimit":"173.0"}]}]},{"title":"CD4-IL-2, Day 60 [N=22;9;7]","categories":[{"measurements":[{"groupId":"OG000","value":"6640.5","lowerLimit":"3213.0","upperLimit":"9520.0"},{"groupId":"OG001","value":"80.0","lowerLimit":"22.0","upperLimit":"253.5"},{"groupId":"OG002","value":"27.0","lowerLimit":"1.0","upperLimit":"174.0"}]}]},{"title":"CD4-IL-2, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"4166.0","lowerLimit":"1477.0","upperLimit":"5347.0"},{"groupId":"OG001","value":"74.0","lowerLimit":"1.0","upperLimit":"127.0"},{"groupId":"OG002","value":"67.0","lowerLimit":"1.0","upperLimit":"120.0"}]}]},{"title":"CD40-TNF-α, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"1.0","upperLimit":"120.0"},{"groupId":"OG001","value":"106.5","lowerLimit":"63.5","upperLimit":"154.5"},{"groupId":"OG002","value":"63.0","lowerLimit":"1.0","upperLimit":"240.0"}]}]},{"title":"CD4-TNF-α, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"793.5","lowerLimit":"226.0","upperLimit":"2093.0"},{"groupId":"OG001","value":"27.5","lowerLimit":"20.0","upperLimit":"65.0"},{"groupId":"OG002","value":"107.0","lowerLimit":"13.0","upperLimit":"147.0"}]}]},{"title":"CD4-TNF-α, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"4286.5","lowerLimit":"2294.0","upperLimit":"6880.0"},{"groupId":"OG001","value":"38.5","lowerLimit":"11.5","upperLimit":"78.5"},{"groupId":"OG002","value":"80.0","lowerLimit":"13.0","upperLimit":"226.0"}]}]},{"title":"CD4-TNF-α, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"2632.0","lowerLimit":"1560.0","upperLimit":"4186.0"},{"groupId":"OG001","value":"54.0","lowerLimit":"17.5","upperLimit":"81.0"},{"groupId":"OG002","value":"54.0","lowerLimit":"13.0","upperLimit":"107.0"}]}]},{"title":"CD40-IFN-γ, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","lowerLimit":"26.0","upperLimit":"212.0"},{"groupId":"OG001","value":"29.5","lowerLimit":"19.0","upperLimit":"113.5"},{"groupId":"OG002","value":"67.0","lowerLimit":"26.0","upperLimit":"147.0"}]}]},{"title":"CD4-IFN-γ, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"413.5","lowerLimit":"119.0","upperLimit":"1373.0"},{"groupId":"OG001","value":"99.0","lowerLimit":"82.5","upperLimit":"147.5"},{"groupId":"OG002","value":"106.0","lowerLimit":"26.0","upperLimit":"199.0"}]}]},{"title":"CD4-IFN-γ, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"1733.5","lowerLimit":"440.0","upperLimit":"3455.0"},{"groupId":"OG001","value":"102.5","lowerLimit":"53.0","upperLimit":"221.0"},{"groupId":"OG002","value":"26.0","lowerLimit":"13.0","upperLimit":"79.0"}]}]},{"title":"CD4-IFN-γ, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"667.0","lowerLimit":"227.0","upperLimit":"2026.0"},{"groupId":"OG001","value":"51.5","lowerLimit":"1.0","upperLimit":"87.0"},{"groupId":"OG002","value":"40.0","lowerLimit":"1.0","upperLimit":"119.0"}]}]}]},{"type":"SECONDARY","title":"Cell Count of CD4+ T Cells","description":"CD4+ T cell counts are defined by values greater than (\\>) 200 cells per cubic millimeters (mm3) at screening for enrolment into the study.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"T cells/cubic millimeter","timeFrame":"At Day 0, 30, 60 and 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"CD4+ T Cells, Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"585","lowerLimit":"416","upperLimit":"651"},{"groupId":"OG001","value":"437","lowerLimit":"318.5","upperLimit":"561"},{"groupId":"OG002","value":"811","lowerLimit":"704","upperLimit":"1050"}]}]},{"title":"CD4+ T Cells, Day 30","categories":[{"measurements":[{"groupId":"OG000","value":"566","lowerLimit":"465","upperLimit":"713"},{"groupId":"OG001","value":"410.5","lowerLimit":"283.5","upperLimit":"527.5"},{"groupId":"OG002","value":"799","lowerLimit":"750","upperLimit":"978"}]}]},{"title":"CD4+ T Cells, Day 60","categories":[{"measurements":[{"groupId":"OG000","value":"567","lowerLimit":"457","upperLimit":"679"},{"groupId":"OG001","value":"368","lowerLimit":"339","upperLimit":"572.5"},{"groupId":"OG002","value":"877","lowerLimit":"745","upperLimit":"1062"}]}]},{"title":"CD 4+ T Cells, Day 210","categories":[{"measurements":[{"groupId":"OG000","value":"548.5","lowerLimit":"426","upperLimit":"680"},{"groupId":"OG001","value":"433","lowerLimit":"377","upperLimit":"534"},{"groupId":"OG002","value":"822","lowerLimit":"741","upperLimit":"1138"}]}]}]},{"type":"SECONDARY","title":"Anti-M72 Specific Antibody Concentrations","description":"Concentrations given in Enzyme-Linked Immunosorbent Assay units per milliliter (EL.U/mL) were expressed in Geometric Mean Concentrations (GMCs).","populationDescription":"The analysis was performed on the ATP cohort for immunogenicity, which included all evaluable subjects for whom data concerning immunogenicity outcome variables were available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EL.U/mL","timeFrame":"At Day 0, 30, 60 and 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"title":"Anti-M72, Day 0 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"}]}]},{"title":"Anti-M72, Day 30 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.5","upperLimit":"2.9"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"}]}]},{"title":"Anti-M72, Day 60 [N=22;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"282.4","lowerLimit":"177.2","upperLimit":"450.0"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"}]}]},{"title":"Anti-M72, Day 210 [N=21;8;7]","categories":[{"measurements":[{"groupId":"OG000","value":"38.3","lowerLimit":"22.8","upperLimit":"64.2"},{"groupId":"OG001","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"},{"groupId":"OG002","value":"1.4","lowerLimit":"1.4","upperLimit":"1.4"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Significant Highly Active Anti-Retroviral Therapy (HAART) Changes","description":"Recorded significant HAART change refers to one subject switching the Combivir drug to Truvada as planned by personal physician, with no relationship to vaccination, prior to study enrolment.","populationDescription":"The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"From Day 60 to Day 210","groups":[{"id":"OG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."},{"id":"OG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Solicited local/general symptoms: during the 7-day period; Unsolicited AEs: during the 30-day period; SAEs: during the entire study period, from Day 0 up to Day 210.","eventGroups":[{"id":"EG000","title":"GSK692342 Group","description":"Subjects received 2 doses of the GSK692342 vaccine, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30.","seriousNumAffected":2,"seriousNumAtRisk":22,"otherNumAffected":21,"otherNumAtRisk":22},{"id":"EG001","title":"Control Group","description":"Subjects received 2 doses of the GSK AS01E adjuvant, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30.","seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":8,"otherNumAtRisk":8},{"id":"EG002","title":"Placebo Group","description":"Subjects received 2 doses of saline solution, intramuscularly into the deltoid region of the non-dominant arm, at Day 0 and into the deltoid region of the dominant arm, at Day 30.","seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":6,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]}],"otherEvents":[{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":2,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Cd4 lymphocytes decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":2,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Pterygium","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Genital herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":22},{"groupId":"EG001","numAffected":8,"numAtRisk":8},{"groupId":"EG002","numAffected":3,"numAtRisk":7}]},{"term":"Redness","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited general symptom","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":22},{"groupId":"EG001","numAffected":6,"numAtRisk":8},{"groupId":"EG002","numAffected":3,"numAtRisk":7}]},{"term":"Gastrointestinal","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":22},{"groupId":"EG001","numAffected":3,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Solicited general symptom","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":22},{"groupId":"EG001","numAffected":4,"numAtRisk":8},{"groupId":"EG002","numAffected":3,"numAtRisk":7}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":22},{"groupId":"EG001","numAffected":1,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Myalgia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]},{"term":"Temperature (Axillary)","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":8},{"groupId":"EG002","numAffected":1,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D014376","term":"Tuberculosis"}],"ancestors":[{"id":"D009164","term":"Mycobacterium Infections"},{"id":"D000193","term":"Actinomycetales Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}